全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场 - 行业趋势和预测至 2031 年

Customize Your Report Customize Your Report 立即购买 立即购买 免费样本报告 免费样本报告
Home Pharmaceutical Global Age Related Macular Degeneration Amd Disease Anti Vegf Market
请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场 - 行业趋势和预测至 2031 年

  • Pharmaceutical
  • Published Report
  • Dec 2023
  • Global
  • 350 页面
  • 桌子數： 283
  • 图号： 33
立即购买 立即购买

Global Age Related Macular Degeneration Amd Disease Anti Vegf Market

市场规模（十亿美元）

CAGR :  % Diagram

Diagram Forecast Period
 2022 –2029
Diagram Market Size (Base Year)
 USD 13,677.02 Million
Diagram Market Size (Forecast Year)
 USD 22,951.90 Million
Diagram CAGR
 %
Diagram Major Markets Players
  • Regeneron Pharmaceuticals
  • Biogen
  • Outlook Therapeutics
  • Sulentis
  • Novartis

>全球年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场，按类型（干性 AMD 和湿性 AMD）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健等）、分销渠道（直接招标和零售销售）- 行业趋势和预测到 2031 年。

年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场

年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场分析和见解

老年性黄斑变性 (AMD) 是一种可能随着时间的推移而恶化的眼部疾病。它是 60 岁以上人群严重、永久性视力丧失的主要原因。衰老是全球早期 AMD 发病的风险因素之一。世界老年人口正在快速增长。随着年龄的增长，由于慢性病患病率上升，老年患者的数量也在增加。疾病的诊断可以在各个阶段进行，基因检测和视网膜成像是检测疾病的一些技术。疾病诊断主要通过光学成像技术和其他标准流程进行。

年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场

虽然没有治愈方法，但治疗老年性黄斑变性 (AMD) 可能会减缓病情，防止您严重视力丧失。老年性黄斑变性 (AMD) 疾病治疗通常包括药物和诊断产品。这些技术用于到达视网膜受损部位，使治疗变得轻松。

全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场预计将在 2024 年至 2031 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2024 年至 2031 年的预测期内，该市场以 6.8% 的复合年增长率增长，预计到 2031 年将从 2023 年的 136.7702 亿美元达到 229.519 亿美元。

全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地理扩展和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案，以实现您的预​​期目标。各个地区发展中国家零售单位的可扩展性和业务扩展以及与供应商合作安全分销机器和药品是推动预测期内市场需求的主要驱动力。

报告指标

细节

预测期

2024 至 2031 年

基准年

2023

历史岁月

2022 (可定制为 2016-2021)

定量单位

收入（百万美元）

涵盖的领域

类型（干性 AMD 和湿性 AMD）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健等）、分销渠道（直接招标和零售销售）

覆盖国家

美国、加拿大、墨西哥、德国、法国、意大利、英国、西班牙、俄罗斯、奥地利、荷兰、匈牙利、波兰、瑞士、土耳其、挪威、立陶宛、爱尔兰、欧洲其他地区、日本、中国、印度、澳大利亚、新加坡、韩国、马来西亚、泰国、印度尼西亚、菲律宾、越南、亚太其他地区、巴西、阿根廷、秘鲁、南美洲其他地区、南非、埃及、沙特阿拉伯、以色列、阿联酋、科威特以及中东和非洲其他地区

涵盖的市场参与者

Regeneron Pharmaceuticals Inc.、Biogen、Outlook Therapeutics, Inc.、Sulentis, SA、Novartis AG、Genentech, Inc.、Bayer AG、Adverum Biotechnologies, Inc.、Gensight Biologics、REGENXBIO INC.、OCUGEN, INC.、MeiraGTX, Limited、Johnson & Johnson Services, Inc.、IVERIC bio, Inc.、An Astellas Company、KODIAK SCIENCES INC. 和 lonis Pharmaceuticals 等。

市场定义

抗 VEGF 疗法可阻止视网膜中异常血管的生长，这是老年性黄斑变性 (AMD) 等疾病的标志。通过抑制 VEGF 的作用，这些药物可防止血管渗漏和中央视觉区域 (黄斑) 受损。通过眼部注射，它们可减缓视力丧失，在某些情况下，还能改善视力。这种针对性治疗是治疗 AMD 的关键，它通过阻止眼部有问题的血管生长来抑制疾病的进展。

全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场动态

本节旨在了解市场驱动因素、优势、限制和挑战。下面将详细讨论所有这些内容：

驱动程序

  • 老年性黄斑变性患病率上升

由于人口老龄化和预期寿命延长，发达国家中青光眼、白内障和老年性黄斑变性等视力威胁性疾病的患病率预计将上升。这些疾病是西方劳动年龄人口失明的主要原因。据估计，近 60% 的患者在出生后不久就患有严重的视力障碍，这推动了市场的增长。

  • 关键参与者的战略主动性增强

协会，该交易被主要参与者用来扩展到世界不同地区，同时将技术从一个参与者传递给其他参与者，从而增加产品认可和机构研究。

市场参与者采取了各种战略举措，包括建立合作伙伴关系、产品批准和协作等。这些举措有助于他们加强在市场上的存在，并帮助他们促进市场扩张。此外，一些战略举措增加了多个客户对其产品的需求。合作、协议和签署销售协议等战略举措有望推动市场发展。

年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场

机会

  • 加大研发力度

研发是调整治疗方法以治疗不同类型患者的先决条件。每个国家对老年性黄斑变性 (AMD) 治疗和手术的需求都在增加。这就是为什么公司不断专注于研发，以成功地为患者和医护人员提供有效的治疗。

只有以某些方式对个体才能看到其影响，包括有效的增强因素，例如疾病的发展、视力逐渐受损、视网膜组织退化和永久性损伤。

挑战/限制

  • 治疗和手术费用高昂

产品成本是影响市场的主要因素。在老年性黄斑变性 (AMD) 疾病中，通常观察到它们非常复杂，必须精确，其他规格会增加产品成本。此外，长期治疗相关的费用对于中等收入人群来说相当难以负担。重症监护和重症监护病房服务的使用率在世界范围内不断增加，其昂贵的费用是当前医疗保健系统的主要问题。

患有退行性疾病的患者通常需要长期治疗，频繁使用药物和其他服务，从而消耗大量医疗资源。大多数无法承担长期经济费用的患者在治疗初期就出院。但这增加了诊断中出现新并发症的可能性和易感性，这需要额外的医疗资源和治疗，从而抑制了市场的增长。

  • 治疗机会有限

疾病的治疗直接取决于该疾病服务的可及性。由于收入低、资源有限等原因，各类老年性黄斑变性 (AMD) 疾病的治疗率较低，导致医院和专科诊所的可及性有限。

2019 年的一份报告中对药品领域的主要市场参与者进行了采访，他们表示，在欠发达国家，他们面临着提供诊断产品可及性的挑战。全球约有 2.85 亿人患有视力障碍；其中 80% 的人患有可治愈的眼疾，但无法获得足够的护理、产品或可用技术，这增加了失明的患病率，并降低了市场的增长。

最新动态

  • 2023 年 11 月，Regeneron Pharmaceuticals, Inc. 在旧金山举行的美国眼科学会 (AAO) 年会上宣布了 EYLEA HD (阿柏西普) 注射液 8 毫克的长期结果和关键临床数据的新分析。这是一场投资者活动，公司试图吸引投资者，这有助于公司增加研发
  • 2023 年 8 月，安斯泰来制药公司宣布，IZERVAY（avacincaptad pegol 玻璃体内注射液）将获得美国食品药品监督管理局 (FDA) 的批准，用于治疗因年龄相关性黄斑变性 (AMD) 而导致的地图样萎缩 (GA)。在两项 3 期临床试验中，新型补体 C5 抑制剂 IZERVAY 的 12 个月主要终点 GA 进展率显著降低 (p<0.01)，使其成为唯一获批的 GA 治疗药物
  • 2022 年 11 月，Sylentis SA 宣布招募其化合物 SYL1801 的新 II 期剂量探索试验的第一位患者，用于治疗新生血管性年龄相关性黄斑变性 (AMD) 患者。这是一项随机、双盲、II 期试验，有三个平行组，每组受试者将接受不同剂量水平的治疗。该研究已经开始，将在几个欧洲国家的不同中心招募 90 名患者。该试验的主要目的是评估 SYL1801 三种剂量对视力的影响，每天一滴，持续六周，用于新生血管性 AMD 患者
  • 2022 年 5 月，Adverum Biotechnologies, Inc. 宣布，该公司已在美国基因和细胞治疗学会 (ASGCT) 2022 年年会上展示了 ADVM-022 的有效性和安全性结果数据，支持了第 2 阶段开发计划。这将在后续临床试验中评估 ADVM-022 剂量与新的增强型预防性类固醇方案
  • 2022 年 3 月，诺华公司宣布，Beovu (brolucizumab) 6 毫克已获得欧盟委员会 (EC) 的批准，用于治疗糖尿病性黄斑水肿 (DME) 引起的视力障碍。Beovu 最初于 20203 年获得欧盟批准，用于治疗湿性老年性黄斑变性；DME 适应症标志着该药物第二次获得批准。欧洲共同体 (EC) 的裁决适用于所有 27 个欧盟成员国以及列支敦士登、冰岛和挪威

全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场范围

全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场根据类型、最终用户和分销渠道分为三个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

类型

  • 干性 AMD
  • 湿性黄斑变性

根据类型，市场分为干性 AMD 和湿性 AMD。

最终用户

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 家庭医疗保健
  • 其他的

根据最终用户，市场分为医院、专科诊所、门诊手术中心、家庭医疗保健等。

分销渠道

  • 零售销售
  • 直接招标

根据分销渠道，市场分为直接招标和零售。

年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场

区域分析/见解：全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场

全球年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场根据类型、最终用户和分销渠道分为三个显著的部分。

本市场报告涵盖的国家包括美国、加拿大、墨西哥、德国、法国、意大利、英国、西班牙、俄罗斯、奥地利、荷兰、匈牙利、波兰、瑞士、土耳其、挪威、立陶宛、爱尔兰、欧洲其他地区、日本、中国、印度、澳大利亚、新加坡、韩国、马来西亚、泰国、印度尼西亚、菲律宾、越南、亚太其他地区、巴西、阿根廷、秘鲁、南美洲其他地区、南非、埃及、沙特阿拉伯、以色列、阿联酋、科威特以及中东和非洲其他地区。

由于老年性黄斑变性患病率不断上升，北美有望在全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 领域占据主导地位。美国有望在北美地区占据主导地位，因为美国拥有全球最大的研发支出，并与多个国家签订了贸易协议，使其成为最大的消费者诊断和治疗产品市场。由于中国大规模生产老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 产品，并且新兴市场的需求不断增加和扩张，中国有望在亚太地区占据主导地位。由于德国拥有新兴的治疗报销政策，预计德国将在欧洲地区占据主导地位。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响。

年龄相关性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场

竞争格局和份额分析：全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场

全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位、产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。

全球老年性黄斑变性 (AMD) 疾病 - 抗 VEGF 市场的一些主要参与者包括 Regeneron Pharmaceuticals Inc.、Biogen、Outlook Therapeutics, Inc.、Sylentis, SA、Novartis AG、Genentech, Inc.、Bayer AG、Adverum Biotechnologies, Inc.、Gensight Biologics、REGENXBIO INC.、OCUGEN, INC.、MeiraGTx Limited、Johnson & Johnson Services, Inc.、IVERIC bio, Inc.、An Astellas Company、KODIAK SCIENCES INC. 和 Ionis Pharmaceuticals 等。

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTERS_

4.3 PRICING ANALYSIS

4.4 STRATEGIC INITIATIVES

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION

6.1.2 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS

6.1.3 INCREASE IN PIPELINE PRODUCTS

6.1.4 INCREASING GERIATRIC POPULATION

6.1.5 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)

6.2 RESTRAINTS

6.2.1 HIGH COST OF TREATMENT AND PROCEDURES

6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS

6.3 OPPORTUNITIES

6.3.1 INCREASING RESEARCH AND DEVELOPMENT

6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD

6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT

6.4 CHALLENGES

6.4.1 LIMITED ACCESS TO TREATMENT

6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS

7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE

7.1 OVERVIEW

7.2 WET AMD

7.2.1 MEDICATIONS

7.2.1.1 ANTI-VEGF THERAPY

7.2.1.2 OTHERS

7.2.2 SURGERY

7.3 DRY AMD

8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 SPECIALTY CLINICS

8.4 AMBULATORY SURGICAL CENTERS

8.5 HOME HEALTHCARE

8.6 OTHERS

9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 RETAIL SALES

9.2.1 HOSPITAL PHARMACIES

9.2.2 RETAIL PHARMACIES

9.2.3 OTHERS

9.3 DIRECT TENDER

10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION

10.1 OVERVIEW

10.2 NORTH AMERICA

10.2.1 U.S.

10.2.2 CANADA

10.2.3 MEXICO

10.3 EUROPE

10.3.1 GERMANY

10.3.2 FRANCE

10.3.3 U.K.

10.3.4 RUSSIA

10.3.5 ITALY

10.3.6 SPAIN

10.3.7 NETHERLANDS

10.3.8 SWITZERLAND

10.3.9 POLAND

10.3.10 TURKEY

10.3.11 AUSTRIA

10.3.12 HUNGARY

10.3.13 NORWAY

10.3.14 IRELAND

10.3.15 LITHUANIA

10.3.16 REST OF EUROPE

10.4 ASIA-PACIFIC

10.4.1 CHINA

10.4.2 JAPAN

10.4.3 INDIA

10.4.4 SOUTH KOREA

10.4.5 AUSTRALIA

10.4.6 SINGAPORE

10.4.7 THAILAND

10.4.8 INDONESIA

10.4.9 PHILIPPINES

10.4.10 MALAYSIA

10.4.11 VIETNAM

10.4.12 REST OF ASIA-PACIFIC

 

10.5 SOUTH AMERICA

10.5.1 BRAZIL

10.5.2 ARGENTINA

10.5.3 PERU

10.5.4 REST OF SOUTH AMERICA

10.6 MIDDLE EAST AND AFRICA

10.6.1 SOUTH AFRICA

10.6.2 SAUDI ARABIA

10.6.3 U.A.E.

10.6.4 ISRAEL

10.6.5 EGYPT

10.6.6 KUWAIT

10.6.7 REST OF SOUTH AFRICA

11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: GLOBAL

12 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 REGENERON PHARMACEUTICALS INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

 

16.2 BAYER AG

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD)

16.3.1 COMPANY SNAPSHOT

16.3.2 COMPANY SHARE ANALYSIS

16.3.3 PRODUCT PORTFOLIO

16.3.4 RECENT DEVELOPMENT

16.4 NOVARTIS AG

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.4.5.1 AGREEMENT

16.5 IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.)

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 ADVERUM BIOTECHNOLOGIES, INC.

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 BIOGEN

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 GENSIGHT BIOLOGICS

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

 

16.9 IONIS PHARMACEUTICALS

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 JOHNSON &JOHNSON SERVICES, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENTS

16.11 KODIAK SCIENCES INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENTS

16.12 MEIRAGTX LIMITED

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENTS

16.13 OCUGEN, INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 OUTLOOK THERAPEUTICS, INC.

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENT

16.15 REGENXBIO INC.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENTS

16.16 SYLENTIS, S.A.

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

表格列表

TABLE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 2 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 3 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF, BY REGION, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 19 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 20 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 23 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 24 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 25 U.S. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 26 U.S. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 27 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 28 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 29 U.S. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 30 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 31 CANADA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 32 CANADA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 33 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 34 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 35 CANADA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 36 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 37 MEXICO WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 38 MEXICO MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 39 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 40 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 41 MEXICO RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 42 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 43 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 44 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 45 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 46 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 47 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 48 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 49 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 50 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 51 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 52 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 53 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 54 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 55 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 56 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 57 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 58 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 59 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 60 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 61 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 62 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 63 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 64 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 65 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 66 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 67 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 68 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 69 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 70 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 71 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 72 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 73 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 74 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 75 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 76 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 77 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 78 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 79 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 80 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 81 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 82 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 83 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 84 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 85 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 86 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 87 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 88 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 89 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 90 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 91 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 92 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 93 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 94 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 95 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 96 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 97 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 98 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 99 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 100 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 101 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 102 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 103 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 104 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 105 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 106 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 107 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 108 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 109 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 110 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 111 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 112 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 113 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 114 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 115 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 116 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 117 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 118 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 119 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 120 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 121 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 122 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 123 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 124 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 125 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 126 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 127 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 128 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 129 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 130 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 131 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 132 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 133 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 134 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 135 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 136 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 137 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 138 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 139 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 140 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 141 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 142 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 143 ASIA-PACIFIC MEDICATION IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 144 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 145 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 146 ASIA-PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 147 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 148 CHINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 149 CHINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 150 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 151 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 152 CHINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 153 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 154 JAPAN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 155 JAPAN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 156 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 157 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 158 JAPAN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 159 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 160 INDIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 161 INDIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 162 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 163 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 164 INDIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 165 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 166 SOUTH KOREA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 167 SOUTH KOREA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 168 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 169 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 170 SOUTH KOREA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 171 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 172 AUSTRALIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 173 AUSTRALIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 174 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 175 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 176 AUSTRALIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 177 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 178 SINGAPORE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 179 SINGAPORE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 180 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 181 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 182 SINGAPORE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 183 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 184 THAILAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 185 THAILAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 186 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 187 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 188 THAILAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 189 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 190 INDONESIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 191 INDONESIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 192 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 193 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 194 INDONESIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 195 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 196 PHILIPPINES WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 197 PHILIPPINES MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 198 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 199 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 200 PHILIPPINES RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 201 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 202 MALAYSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 203 MALAYSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 204 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 205 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 206 MALAYSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 207 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 208 VIETNAM WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 209 VIETNAM MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 210 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 211 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 212 VIETNAM RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 213 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 214 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 215 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 216 SOUTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 217 SOUTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 218 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 219 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 220 SOUTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 221 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 222 BRAZIL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 223 BRAZIL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 224 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 225 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 226 BRAZIL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 227 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 228 ARGENTINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 229 ARGENTINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 230 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 231 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 232 ARGENTINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 233 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 234 PERU WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 235 PERU MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 236 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 237 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 238 PERU RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 239 REST OF SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 240 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 241 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 242 MIDDLE EAST AND AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 243 MIDDLE EAST AND AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 244 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 245 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 246 MIDDLE EAST AND AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 247 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 248 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 249 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 250 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 251 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 252 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 253 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 254 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 255 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 256 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 257 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 258 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 259 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 260 U.A.E. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 261 U.A.E. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 262 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 263 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 264 U.A.E. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 265 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 266 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 267 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 268 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 269 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 270 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 271 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 272 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 273 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 274 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 275 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 276 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 277 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 278 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 279 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 280 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 281 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 282 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 283 REST OF SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)

图片列表

FIGURE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION

FIGURE 2 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: END USER COVERAGE GRID

FIGURE 10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST RATE IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 13 AN INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE GROWTH OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 14 WET AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN 2023 AND 2031

FIGURE 15 EUROPE IS THE FASTEST-GROWING MARKET IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET

FIGURE 17 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2023

FIGURE 18 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2024-2031 (USD MILLION)

FIGURE 19 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 20 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, LIFELINE CURVE

FIGURE 21 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2023

FIGURE 22 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 23 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, CAGR (2024-2031)

FIGURE 24 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, LIFELINE CURVE

FIGURE 25 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 26 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 27 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 28 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 29 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SNAPSHOT (2023)

FIGURE 30 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)

FIGURE 31 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)

FIGURE 32 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)

FIGURE 33 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2031. .
The Global Age Related Macular Degeneration Amd Disease Anti Vegf Market size was valued at USD 13677.02 USD Million in 2021.
The Global Age Related Macular Degeneration Amd Disease Anti Vegf Market is projected to grow at a CAGR of 6.8% during the forecast period of 2022 to 2029.
The major players operating in the market include Regeneron Pharmaceuticals, Biogen, Outlook Therapeutics, Sulentis, Novartis, Genentech, Bayer, Adverum Biotechnologies, Gensight Biologics, REGENXBIO, OCUGEN, MeiraGTX, Johnson & Johnson Services, IVERIC bio, KODIAK SCIENCES, Ionis Pharmaceuticals.
The market report covers data from the U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa.

浏览相关页面

Banner